Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
1 finding from 1 review